Downstream processing of oligonucleotides: meeting regulatory and commercial demands
Nucleic Acid Insights · 30.06.2026 · 3 (5) · 325–333
DOI: 10.18609/nuc.2026.038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Insights, online erschienen am 30.06.2026. Verfasst von Piotr Putaj und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
“Each conjugation strategy brings its own set of purification challenges, and these must be worked through systematically before scale‑up.” As the pipeline of oligonucleotide therapeutics continues to expand, and as approved compounds begin to address broader patient populations, the demands placed on downstream processing are intensifying. Purification, finishing, and impurity control must now operate at greater scale, with higher complexity molecules, and under increasingly scrutinized regulatory frameworks. Nucleic Acid Insights brought together a panel of experts to discuss the key challenges and emerging solutions in this space: Piotr Putaj (Director of Oligonucleotide Chemistry, VICO Therapeutics), Jared Jackson (Oligonucleotide Scientist), and Maria del Carme Pons Royo (Postdoctoral Researcher, MIT). The discussion covers purification strategies, impurity management, conjugation complexity, the role of analytics, and the future of the field, alongside the distinct downstream challenges presented by mRNA therapeutics.
Zitieren
APA
Putaj, P., Jackson, J., & Royo, M. D. C. P. (2026). Downstream processing of oligonucleotides: meeting regulatory and commercial demands. Nucleic Acid Insights, 3(5), 325–333. https://doi.org/10.18609/nuc.2026.038
Vancouver
Putaj P, Jackson J, Royo MDCP. Downstream processing of oligonucleotides: meeting regulatory and commercial demands. Nucleic Acid Insights. 2026;3(5):325–333. doi:10.18609/nuc.2026.038
BibTeX
@article{Putaj2026,
author = {Putaj, Piotr and Jackson, Jared and Royo, Maria del Carme Pons},
title = {Downstream processing of oligonucleotides: meeting regulatory and commercial demands},
journal = {Nucleic Acid Insights},
year = {2026},
volume = {3},
number = {5},
pages = {325–333},
doi = {10.18609/nuc.2026.038}
}
EUVIMED